Afficher la notice abrégée

Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics

dc.rights.licenseopenen_US
dc.contributor.authorHUMBERT, Marc
dc.contributor.authorBOURDIN, Arnaud
dc.contributor.authorTAILLE, Camille
dc.contributor.authorKAMAR, Driss
dc.contributor.authorTHONNELIER, Celine
dc.contributor.authorLAJOINIE, Audrey
dc.contributor.authorRIGAULT, Alexandre
dc.contributor.authorDESCHILDRE, Antoine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
dc.date.accessioned2022-06-14T13:23:06Z
dc.date.available2022-06-14T13:23:06Z
dc.date.issued2022-05-26
dc.identifier.issn1399-3003 (Electronic) 0903-1936 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140208
dc.description.abstractEnThis real-life study aimed to assess omalizumab treatment patterns in adult and pediatric asthma patients, and to describe asthma control and healthcare resource use (HCRU) at omalizumab initiation and discontinuation.The French Healthcare Database System (SNDS) was used to identify asthma patients aged ≥6 years who initiated omalizumab for at least 16 weeks from 2009 to 2019. We examined omalizumab treatment patterns using dispensation records.We identified 16 750 adults and 2453 children initiating omalizumab. Median treatment persistence before discontinuation was 51.2 [95%CI 49.3-53.4] and 53.7 [50.6-56.4] months. At two years of omalizumab exposure, rate of hospitalization for asthma decreased by 75% and use of oral corticosteroids (OCS) by 30%, in adults and children. Among adults who discontinued omalizumab while asthma was controlled, 70%, 39% and 24% remained controlled and did not resume omalizumab at 1, 2 and 3 years after discontinuation. These proportions were higher in children (76%, 44% and 33%). Over two years of follow-up after discontinuation, HCRU remained stable in adults and children, notably rate of hospitalizations for asthma (none before T(STOP), 1.3% and 0.6% at two years) and use of OCS (in adults and children, respectively: 20.0% and 20.2% before T(STOP), 33.3% and 24.6% at two years).This is the first large-scale study describing omalizumab real-life exposure patterns in adult and pediatric asthma patients in France with more than 10 years of follow-up. We showed the long-term maintenance of low HCRU in adults and children who discontinued omalizumab while asthma was controlled, notably for OCS use and hospitalizations for asthma.
dc.language.isoENen_US
dc.rightsAttribution - Pas d’Utilisation Commerciale 3.0 France (CC BY-NC 3.0 FR)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/fr/
dc.title.enReal-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics
dc.typeArticle de revueen_US
dc.identifier.doi10.1183/13993003.03130-2021en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35618272en_US
bordeaux.journalEuropean Respiratory Journalen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDNovartis Pharmaen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Respiratory%20Journal&rft.date=2022-05-26&rft.eissn=1399-3003%20(Electronic)%200903-1936%20(Linking)&rft.issn=1399-3003%20(Electronic)%200903-1936%20(Linking)&rft.au=HUMBERT,%20Marc&BOURDIN,%20Arnaud&TAILLE,%20Camille&KAMAR,%20Driss&THONNELIER,%20Celine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_ERJ_2022_Humbert.pdf
Taille:
835.8Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée